Clinical Research Directory
Browse clinical research sites, groups, and studies.
Engineered Dendritic Cell Vaccines for Multiple Myeloma
Sponsor: Shenzhen Geno-Immune Medical Institute
Summary
The purpose of this study is to determine the feasibility, safety, and efficacy of dendritic cell (DC) vaccines in the treatment of multiple myeloma (MM) or plasmacytoma based on immune-modified DC vaccines (DCvac). This approach is aimed to achieve prolonged maintenance of remission in multiple myeloma or plasmacytoma patients.
Official title: Engineered Dendritic Cell Vaccines for Remission Maintenance in Multiple Myeloma Patients
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2024-05-11
Completion Date
2027-12-31
Last Updated
2024-06-10
Healthy Volunteers
No
Conditions
Interventions
DC vaccines
Antigen-presenting and immune modifying DCvacs to treat MM
Locations (2)
Shenzhen Geno-immune Medical Institute
Shenzhen, Guangdong, China
The Regional Hematology Center in Clinical Hospital No. 2 of the Ministry of Health
Vladivostok, Russia